Core Viewpoint - The company reported significant revenue growth and a reduction in losses for the six months ending December 31, 2025, indicating a positive trend in market demand and consumption [1] Financial Performance - The company achieved a revenue of HKD 352 million, representing a year-on-year increase of 118.65% [1] - The loss attributable to shareholders for the period was HKD 5.939 million, a decrease of 56.53% compared to the previous year [1] - The loss per share was HKD 0.0333 [1] Gross Profit Analysis - The gross profit for the six months ending December 31, 2025, was approximately HKD 35.7 million, with a gross margin of 10.1% [1] - In comparison, the gross profit for the six months ending December 31, 2024, was about HKD 21.1 million, with a gross margin of approximately 13.1% [1] - The gross profit increased by approximately HKD 14.5 million, while the gross margin decreased by 3.0% [1]
玮俊生物科技(00660)发布中期业绩，股东应占亏损593.9万港元 同比减少56.53%